Dipesh Uprety
Wayne State University
EpidemiologyCancerInternal medicineSurgeryOncologyStage (cooking)Lung cancerSurvival rateMultiple myelomaChronic lymphocytic leukemiaMyeloid leukemiaDiseaseLymphomaMalignancyRelative survivalPopulationNon small cellIn patientIncidence (epidemiology)Cancer researchProportional hazards modelLog-rank testMedicine
58Publications
9H-index
195Citations
Publications 57
Newest
#1Dipesh UpretyH-Index: 9
#2Jordi RemonH-Index: 27
Last. Alex A. Adjei (Mayo Clinic)H-Index: 84
view all 0 authors...
Source
Source
Source
#1Dipesh Uprety (Mayo Clinic)H-Index: 9
#2Andrew J. Borgert (Gundersen Health System)H-Index: 17
Last. Benjamin M. Parsons (Gundersen Health System)H-Index: 9
view all 4 authors...
Abstract: Introduction The AJCC 8th staging classification system for non-small-cell lung cancer was based on data from a multinational study consisting of 94,708 patients. African Americans were not included in this large database. Methods The authors aimed to compare the performance of the AJCC 8th staging system with the 7th in predicting overall survival among African Americans utilizing the National Cancer Database. Cases with T- and M- categories were classified into two groups based on AJ...
Source
Source
#1Subash GhimireH-Index: 4
#2Swapna RaviH-Index: 1
Last. Dipesh Uprety (Gundersen Health System)H-Index: 9
view all 8 authors...
Sepsis is a global health burden that needs intensive medical care. Thrombocytopenia in sepsis is well known to increase morbidity as well as mortality. Several studies have been performed both in animal models and in humans to understand the mechanism by which sepsis causes thrombocytopenia. Recent studies have shown that inhibiting thrombocytopenia improves outcomes in sepsis patients. Understanding these mechanisms to identify targets in use of newer treatment modalities besides using resusci...
4 CitationsSource
2 CitationsSource
#1Dipesh Uprety (Mayo Clinic)H-Index: 9
#2Thorvardur R. Halfdanarson (Mayo Clinic)H-Index: 28
Last. Konstantinos Leventakos (Mayo Clinic)H-Index: 14
view all 4 authors...
OPINION STATEMENT Bronchial carcinoids are uncommon tumors accounting for 20 to 30% of all neuroendocrine tumors and about 1-2% of all cancers of pulmonary origin. Bronchial carcinoids are well-differentiated neuroendocrine tumors and have a favorable survival outcome when compared with other subtypes of lung cancers. Treatment of bronchial carcinoids is not simple owing to intricacy of symptom presentation and heterogeneity of disease biology. Successful treatment of patients requires a multimo...
3 CitationsSource
#1Dipesh UpretyH-Index: 9
#2Kaushal Parikh (Hackensack University Medical Center)H-Index: 7
Last. Konstantinos LeventakosH-Index: 14
view all 5 authors...
Lung cancer is the most common cancer worldwide. Approximately 18% of all deaths related to cancer are associated with lung cancer. Management of non-small cell lung cancer (NSCLC) has been changing rapidly in last few years. For patients with unresectable non-metastatic disease, maintenance durvalumab is now given after offering chemo-radiation concurrently based on the result from the PACIFIC trial. Management of metastatic disease greatly depends on the status of sensitizing driver mutation a...
2 CitationsSource
#1Dipesh Uprety (Mayo Clinic)H-Index: 9
#2Sumithra J. Mandrekar (Mayo Clinic)H-Index: 55
Last. Alex A. Adjei (Mayo Clinic)H-Index: 84
view all 5 authors...
Lung cancer is the leading cause of cancer-related deaths worldwide. Patients with resectable non-small cell lung cancer (NSCLC) are often treated with surgery and adjuvant chemotherapy. However, these patients continue to have a high risk of recurrence and death. Unfortunately, there has been little progress in the treatment of resectable NSCLC over the last several decades. Neoadjuvant therapy, which has been considered an approach to improve survival for resectable NSCLC patients, is a hotly ...
24 CitationsSource